JNJ 42165279

Drug Profile

JNJ 42165279

Alternative Names: JNJ-42165279

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen-Cilag
  • Class Amides; Anxiolytics; Benzodioxoles; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anxiety disorders

Most Recent Events

  • 10 Sep 2018 Janssen Research & Development plans a phase II trial for Autistic-disorder in the US , (NCT03664232)
  • 13 Aug 2018 Janssen completes its phase I pharmacokinetics trial in Japanese volunteers in USA (PO) (NCT03564379)
  • 09 Aug 2018 Janssen completes its phase IIa trial for Anxiety disorder in USA, Australia and Canada (NCT02432703)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top